Metraipolis › archive › dc_656fdf55311c

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy — Europe PMC PMID:41002573

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41002573
DOI
10.3390/curroncol32090503
License (as archived)
solo-consultazione
Archived
2026-11-10T01:01:59.001Z
SHA-256 of the archived text
bf1eff8534f3c912bd3773b91b77241bbdad2054325e4a97d962748b74112e81
Stable URL of this page
https://metraipolis.com/documento/dc_656fdf55311c

How to cite

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy — Europe PMC PMID:41002573 — Europe PMC (en), https://europepmc.org/article/MED/41002573 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_656fdf55311c (Metraipolis archive dc_656fdf55311c, sha256 bf1eff8534f3c912bd3773b91b77241bbdad2054325e4a97d962748b74112e81)
BibTeX
@misc{dc656fdf55311c,
  title = {Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy — Europe PMC PMID:41002573},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41002573},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_656fdf55311c; sha256 bf1eff8534f3c912bd3773b91b77241bbdad2054325e4a97d962748b74112e81},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41002573. Agents can read the archived copy with the MCP tool read_document.